Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

NCT ID: NCT04446117

Last Updated: 2025-12-18

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 575 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-10-19
• Study Completion Date: 2026-10-16

Brief Summary

This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.

Detailed Description

The primary objective of this study is to evaluate the efficacy of cabozantinib (XL184) in combination with atezolizumab versus a second NHT (abiraterone or enzalutamide) in subjects with mCRPC who have previously been treated with one, and only one, NHT (e.g. abiraterone, apalutamide, darolutamide, or enzalutamide) to treat metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic CRPC (M0 CRPC), or mCRPC, and who have measurable extrapelvic disease. The multiple primary efficacy endpoints comparing the experimental arm and control arm are Duration of Progression Free Survival (PFS) per RECIST 1.1 by Blinded Independent Radiology Committee (BIRC) and Duration of Overall Survival (OS). The secondary efficacy endpoint is Objective Response Rate (ORR) per RECIST 1.1 per BIRC.

Conditions

Metastatic Prostate Cancer; Prostate Adenocarcinoma

Keywords

prostate cancer; castration-resistant prostate cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental Arm

Subjects with mCRPC will receive cabozantinib 40mg oral, qd + atezolizumab 1200mg infusion, q3w

Group Type: EXPERIMENTAL

Cabozantinib

Intervention Type: DRUG

Supplied as 20-mg tablets; administered orally daily at 40mg

Atezolizumab

Intervention Type: DRUG

Supplied as 1200 mg/20 mL vials; administered as an IV infusion once every 3 weeks (q3w)

Control Arm

Subjects with mCRPC will receive active comparator of EITHER abiraterone 1000mg oral, qd + prednisone 5 mg oral, bid; OR enzalutamide 160mg oral, qd as designated by the Investigator prior to randomization

Group Type: ACTIVE_COMPARATOR

Abiraterone Acetate

Intervention Type: DRUG

Supplied as 500 mg tablets; administered orally daily at 1000mg with prednisone 5 mg orally bid

Enzalutamide

Intervention Type: DRUG

Supplied as 40 mg capsules; administered orally daily at 160mg

Prednisone

Intervention Type: DRUG

Supplied as 5 mg tablets; administered orally bid at 5 mg with abiraterone 1000mg orally daily

Interventions

Cabozantinib

Supplied as 20-mg tablets; administered orally daily at 40mg

Intervention Type: DRUG

Atezolizumab

Supplied as 1200 mg/20 mL vials; administered as an IV infusion once every 3 weeks (q3w)

Intervention Type: DRUG

Abiraterone Acetate

Supplied as 500 mg tablets; administered orally daily at 1000mg with prednisone 5 mg orally bid

Intervention Type: DRUG

Enzalutamide

Supplied as 40 mg capsules; administered orally daily at 160mg

Intervention Type: DRUG

Prednisone

Supplied as 5 mg tablets; administered orally bid at 5 mg with abiraterone 1000mg orally daily

Intervention Type: DRUG

Other Intervention Names

XL184; Cabometyx®; Tecentriq®; Abiraterone; Zytiga; Xtandi

Eligibility Criteria

Inclusion Criteria

• Men with histologically or cytologically confirmed adenocarcinoma of the prostate
• Prior treatment with one, and only one, NHT (eg, abiraterone, apalutamide, darolutamide, or enzalutamide) for castration-sensitive locally advanced (T3 or T4) or mCSPC, M0 CRPC, or mCRPC
• Surgical or medical castration, with serum testosterone ≤ 50 ng/dL (≤ 1.73 nmol/L) at screening
• Measurable (extrapelvic soft tissue) metastatic disease per Investigator assessment defined by at least one of the following: measurable visceral disease (eg, adrenal, kidney, liver, lung, pancreas, spleen) per RECIST 1.1; OR measurable extrapelvic adenopathy (ie, adenopathy above the aortic bifurcation)
• Progressive disease at study entry as defined by specific criteria for prostate specific antigen (PSA) progression OR soft tissue disease progression in the opinion of the Investigator (Note: subjects with bone disease progression alone are not eligible)
• Age ≥ 18 years old or meeting country definition of adult, whichever is older, on the day of consent
• ECOG performance status of 0 or 1
• Recovery to baseline or ≤ Grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) v5 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy in the opinion of the Investigator
• Adequate organ and marrow function based upon specific laboratory assessments obtained within 21 days prior to randomization
• Understanding and ability to comply with protocol requirements

Exclusion Criteria

• Any prior nonhormonal therapy initiated for the treatment of mCRPC
• Receipt of abiraterone within 1 week; cyproterone within 10 days; or flutamide, nilutamide, bicalutamide, enzalutamide, or other androgen-receptor inhibitors within 2 weeks before randomization
• Radiation therapy within 4 weeks (2 weeks for bone metastases) prior to randomization (subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible)
• Known brain metastases or cranial epidural disease unless adequately treated and clinically stable at least 4 weeks prior to randomization
• Symptomatic or impending spinal cord compression or cauda equina syndrome
• Concomitant anticoagulation with oral anticoagulants (some specific exceptions apply)
• Administration of a live, attenuated vaccine within 30 days prior to randomization
• Systematic treatment with, or any condition requiring, either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to randomization
• Uncontrolled, significant intercurrent or recent illness
• Major surgery within 4 weeks prior to randomization
• Corrected QT interval calculated by the Fridericia formula (QTcF) > 480 ms per ECG within 21 days before randomization
• Inability or unwillingness to swallow pills or receive IV administration
• Previously identified allergy or hypersensitivity to components of the study treatment formulations or history of severe infusion-related reactions to monoclonal antibodies
• Any other active malignancy at time of randomization or diagnosis of another malignancy within 2 years prior to randomization that requires active treatment (some exceptions apply such as locally curable cancers that have apparently been cured).

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Roche-Genentech

INDUSTRY

Sponsor Role: collaborator

Takeda

INDUSTRY

Sponsor Role: collaborator

Exelixis

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Exelixis Clinical Site #4

Tucson, Arizona, United States

Exelixis Clinical Site #42

Duarte, California, United States

Exelixis Clinical Site #2

Fullerton, California, United States

Exelixis Clinical Site #224

La Jolla, California, United States

Exelixis Clinical Site #3

Marina del Rey, California, United States

Exelixis Clinical Site #114

San Diego, California, United States

Exelixis Clinical Site #125

Santa Monica, California, United States

Exelixis Clinical Site #245

Stanford, California, United States

Exelixis Clinical Site #91

Aurora, Colorado, United States

Exelixis Clinical Site #14

Denver, Colorado, United States

Yale University School of Medicine

New Haven, Connecticut, United States

Yale University, School of Medicine

New Haven, Connecticut, United States

Exelixis Clinical Site #108

Miami, Florida, United States

Winship Cancer Institute of Emory University

Atlanta, Georgia, United States

Exelixis Clinical Site #215

Westwood, Kansas, United States

Exelixis Clinical Site #242

Louisville, Kentucky, United States

Exelixis Clinical Site #6

Baltimore, Maryland, United States

Non-participating Site

Detroit, Michigan, United States

Exelixis Clinical Site #203

Rochester, Minnesota, United States

Exelixis Clinical Site #19

Omaha, Nebraska, United States

Exelixis Clinical Site #144

Las Vegas, Nevada, United States

Exelixis Clinical Site #123

East Brunswick, New Jersey, United States

Non-participating Site

Lawrenceville, New Jersey, United States

Weill Cornell Medical College

New York, New York, United States

Exelixis Clinical Site #198

The Bronx, New York, United States

Exelixis Site #159

Cleveland, Ohio, United States

Exelixis Clinical Site #221

Oklahoma City, Oklahoma, United States

Exelixis Clinical Site #18

Philadelphia, Pennsylvania, United States

Exelixis Clinical Site #201

Pittsburgh, Pennsylvania, United States

Exelixis Clinical Site #1

Nashville, Tennessee, United States

Exelixis Clinical Site #5

Houston, Texas, United States

Exelixis Clinical Site #177

Houston, Texas, United States

Exelixis Clinical Site #259

Houston, Texas, United States

Exelixis Clinical Site #41

Temple, Texas, United States

Exelixis Clinical Site #67

Salt Lake City, Utah, United States

Exelixis Clinical Site #143

Roanoke, Virginia, United States

Exelixis Clinical Site #122

Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina

Exelixis Clinical Site #120

Mar del Plata, Buenos Aires, Argentina

Exelixis Site #170

Pergamino, Buenos Aires, Argentina

Exelixis Clinical Site #210

Córdoba, Córdoba Province, Argentina

Exelixis Clinical Site #152

Viedma, Río Negro Province, Argentina

Exelixis Clinical Site #183

Rosario, Santa Fe Province, Argentina

Exelixis Clinical #261

Rosario, Santa Fe Province, Argentina

Exelixis Clinical Site #200

Buenos Aires, , Argentina

Exelixis Clinical Site #256

Caba, , Argentina

Exelixis Clinical Site #44

Ciudad Autonoma de Buenos Aire, , Argentina

Exelixis Clinical Site #105

La Rioja, , Argentina

Exelixis Clinical Site #124

San Juan, , Argentina

Exelixis Clinical Site #101

San Salvador de Jujuy, , Argentina

Exelixis Clinical Site #151

Garran, Australian Capital Territory, Australia

Exelixis Clinical Site #252

Port Macquarie, New South Wales, Australia

Exelixis Clinical Site #175

Saint Leonards, New South Wales, Australia

Exelixis Clinical Site # 189

Sydney, New South Wales, Australia

Exelixis Site #162

Wollongong, New South Wales, Australia

Exelixis Clinical Site #253

Chermside, Queensland, Australia

Exelixis Clinical Site #103

Launceston, Tasmania, Australia

Exelixis Clinical Site #79

Ballarat, Victoria, Australia

Exelixis Clinical Site #95

Frankston, Victoria, Australia

Exelixis Clinical #262

Geelong, Victoria, Australia

Exelixis Clinical Site #53

Melbourne, Victoria, Australia

Exelixis Clinical Stie #260

Saint Albans, Victoria, Australia

Exelixis Clinical Site #115

Adelaide, , Australia

Exelixis Clinical Site #149

Box Hill, , Australia

Exelixis Clinical Site #156

Linz, Upper Austria, Austria

Exelixis Site #158

Linz, Upper Austria, Austria

Exelixis Clinical Site #218

Vienna, , Austria

Exelixis Clinical Site #126

Bonheiden, Antwerpen, Belgium

Exelixis Clinical Site #39

Ghent, Oost-Vlaanderen, Belgium

Exelixis Clinical Site #141

Brussels, , Belgium

Exelixis Site #165

Roeselare, , Belgium

Exelixis Site #163

Curitiba, Paraná, Brazil

Exelixis Clinical Site #204

Curitiba, Paraná, Brazil

Exelixis Clinical Site #171

Rio de Janeiro, Rio de Janeiro, Brazil

Exelixis Site #157

Porto Alegre, Rio Grande do Sul, Brazil

Exelixis Clinical Site #132

Blumenau, Santa Catarina, Brazil

Exelixis Clinical Site #191

Campinas, São Paulo, Brazil

Exelixis Clinical Site #128

Ribeirão Preto, São Paulo, Brazil

Exelixis Clinical Site #106

São José do Rio Preto, São Paulo, Brazil

Exelixis Site #161

São Paulo, São Paulo, Brazil

Exelixis Clinical Site #154

Barretos, , Brazil

Exelixis Clinical Site #140

Fortaleza, , Brazil

Exelixis Clinical Site #153

Porto Alegre, , Brazil

Exelixis Clinical Site #145

Ribeirão Preto, , Brazil

Exelixis Clinical Site #116

Santa Cruz do Sul, , Brazil

Exelixis Clinical Site #69

Edmonton, Alberta, Canada

Exelixis Clinical Site #112

Kelowna, British Columbia, Canada

Exelixis Clinical Site #147

Moncton, New Brunswick, Canada

Exelixis Clinical Site #83

Hamilton, Ontario, Canada

Exelixis Clinical Site #127

London, Ontario, Canada

Exelixis Clinical Site #7

Oakville, Ontario, Canada

Exelixis Clinical Site #178

Granby, Quebec, Canada

Exelixis Site #160

Montreal, Quebec, Canada

Exelixis Clinical Site #247

Viña del Mar, Región de Valparaíso, Chile

Exelixis Clinical #263

Santiago, Santiago Metropolitan, Chile

Exelixis Clinical Site #139

Santiago, Santiago Metropolitan, Chile

Exelixis Clinical Site #142

Providencia, , Chile

Exelixis Clinical Site #148

Recoleta, , Chile

Exelixis Clinical Site #90

Santiago, , Chile

Exelixis Clinical Site #113

Temuco, , Chile

Exelixis Clinical Site #119

Valparaíso, , Chile

Exelixis Clinical Site #63

Prague, Prague, Czechia

Exelixis Clinical Site #129

Brno, , Czechia

Exelixis Clinical Site #130

Olomouc, , Czechia

Exelixis Clinical Site #80

Prague, , Czechia

Exelixis Clinical Site #31

Prague, , Czechia

Exelixis Clinical Site #47

Prague, , Czechia

Exelixis Clinical Site #134

Brest, , France

Exelixis Clinical Site #77

Clermont-Ferrand, , France

Exelixis Clinical Site #155

Dijon, , France

Exelixis Clinical Site #74

Hyères, , France

Exelixis Clinical Site #222

La Roche-sur-Yon, , France

Exelixis Clinical Site #146

Nîmes, , France

Exelixis Clinical Site #38

Paris, , France

Exelixis Clinical Site #66

Quimper, , France

Exelixis Clinical Site #214

Reims, , France

Exelixis Clinical Site #135

Saint-Grégoire, , France

Exelixis Clinical Site #213

Strasbourg, , France

Exelixis Clinical Site #36

Strasbourg, , France

Exelixis Clinical Site #73

Toulouse, , France

Exelixis Clinical Site #85

Toulouse, , France

Exelixis Clinical Site #230

Vandœuvre-lès-Nancy, , France

Exelixis Clinical Site #16

Tbilisi, , Georgia

Exelixis Clinical Site #9

Tbilisi, , Georgia

Exelixis Clinical Site #10

Tbilisi, , Georgia

Exelixis Clinical Site #11

Tbilisi, , Georgia

Exelixis Clinical Site #15

Tbilisi, , Georgia

Exelixis Clinical Site #8

Tbilisi, , Georgia

Exelixis Clinical Site #176

Nürtingen, Baden-Wurttemberg, Germany

Exelixis Clinical Site #180

Duisburg, North Rhine-Westphalia, Germany

Exelixis Clinical Site #98

Gütersloh, North Rhine-Westphalia, Germany

Exelixis Clinical Site #179

Münster, North Rhine-Westphalia, Germany

Exelixis Clinical Site #185

Lübeck, Schleswig-Holstein, Germany

Exelixis Clinical Site #227

Berlin, , Germany

Exelixis Clinical Site #239

Hamburg, , Germany

Exelixis Clinical Site #273

Hanover, , Germany

Exelixis Clinical Site #136

Tübingen, , Germany

Exelixis Clinical Site #238

Athens, Attica, Greece

Exelixis Clinical Site #93

Cholargós, Attica, Greece

Exelixis Clinical Site #202

Marousi, Attica, Greece

Exelixis Clinical Site #92

Marousi, Attica, Greece

Exelixis Clinical Site #244

Nea Kifissia, Attica, Greece

Exelixis Clinical Site #99

Neo Faliro, Attica, Greece

Exelixis Clinical Site #45

Heraklion, Crete, Greece

Exelixis Clinical Site #64

Thessaloniki, Macedonia, Greece

Exelixis Clinical Site #97

Larissa, Thessaly, Greece

Exelixis Clinical Site #118

Budapest, , Hungary

Exelixis Clinical Site #207

Budapest, , Hungary

Exelixis Clinical Site #57

Budapest, , Hungary

Exelixis Clinical Site #109

Budapest, , Hungary

Exelixis Clinical Site #240

Debrecen, , Hungary

Exelixis site #167

Gyula, , Hungary

Exelixis Clinical Site #55

Haifa, , Israel

Exelixis Clinical Site #27

Jerusalem, , Israel

Exelixis Clinical Site #150

Petah Tikva, , Israel

Exelixis Clinical Site #117

Ramat Gan, , Israel

Exelixis Clinical Site #30

Safed, , Israel

Exelixis Clinical Site #35

Tel Aviv, , Israel

Exelixis Site #168

Meldola, FC, Italy

Exelixis Clinical Site #246

Rozzano, Milano, Italy

Exelixis Site #156

Sondrio, SO, Italy

Exelixis Clinical Site #199

Trento, Trentino-Alto Adige, Italy

Exelixis Clinical Site #217

Ancona, , Italy

Exelixis Clinical Site #121

Florence, , Italy

Exelixis Clinical Site #192

Milan, , Italy

Exelixis Clinical Site #258

Milan, , Italy

Exelixis Clinical #267

Parma, , Italy

Exelixis Clinical Site #237

Pavia, , Italy

Exelixis Clinical Site #107

Perugia, , Italy

Exelixis Clinical #269

Pisa, , Italy

Exelixis Clinical Site #62

Roma, , Italy

Exelixis Clinical Site #234

Roma, , Italy

Exelixis Clinical Site #96

Terni, , Italy

Exelixis Clinical Site #232

Toyota-shi, Aichi-ken, Japan

Exelixis Clinical Site #100

Akita, Akita, Japan

Exelixis Clinical Site #104

Hirosaki, Aomori, Japan

Exelixis Clinical Site #43

Kashiwa-shi, Chiba, Japan

Exelixis Clinical Site #54

Sakura-shi, Chiba, Japan

Exelixis Clinical Site #72

Sapporo, Hokkaido, Japan

Exelixis Clinical Site #37

Sapporo, Hokkaido, Japan

Exelixis Clinical Site #70

Kobe, Hyōgo, Japan

Exelixis Clinical Site #52

Kobe, Hyōgo, Japan

Exelixis Clinical Site #84

Kita-gun, Kagawa-ken, Japan

Exelixis Clinical Site #68

Sagamihara, Kanagawa, Japan

Exelixis Clinical Site #22

Yokohama, Kanagawa, Japan

Exelixis Clinical Site #211

Natori-shi, Miyagi, Japan

Exelixis Clinical Site #88

Chūōku, Osaka-shi, Japan

Exelixis Clinical Site #51

Hidaka, Saitama, Japan

Exelixis Clinical Site #216

Shizuoka, Shizuoka, Japan

Exelixis Clinical Site #65

Shinjuku-Ku, Tokyo, Japan

Exelixis Clinical Site #61

Ube, Yamaguchi, Japan

Exelixis Clinical Site #78

Chiba, , Japan

Exelixis Clinical Site #209

Fukuoka, , Japan

Exelixis Clinical Site #26

Nagano, , Japan

Exelixis Clinical Site #81

Ōsaka-sayama, , Japan

Exelixis Clinical Site #75

Tokyo, , Japan

Exelixis Clinical Site #32

Wakayama, , Japan

Exelixis Clinical Site #206

Tuxtla Gutiérrez, Chiapas, Mexico

Exelixis Clinical Site #254

León, Guanajuato, Mexico

Exelixis Clinical Site #212

Guadalajara, Jalisco, Mexico

Exelixis Clinical Site #173

Guadalajara, Jalisco, Mexico

Exelixis Clinical Site #219

Zapopan, Jalisco, Mexico

Exelixis Clinical Site #187

Mexico City, Mexico City, Mexico

Exelixis Clinical Site #257

Monterrey, Nuevo León, Mexico

Exelixis Clinical Site #172

Querétaro City, Querétaro, Mexico

Exelixis Clinical Site #182

Querétaro City, Querétaro, Mexico

Exelixis Clinical Site #250

San Luis Potosí City, San Luis Potosí, Mexico

Exelixis Clinical Site #184

San Luis Potosí City, San Luis Potosí, Mexico

Exelixis Clinical Site #208

Culiacán, Sinaloa, Mexico

Exelixis Clinical Site #174

Mexico City, , Mexico

Exelixis Clinical Site #272

Puebla City, , Mexico

Exelixis Clinical Site #243

Otwock, Masovian Voivodeship, Poland

Exelixis Clinical Site #82

Bydgoszcz, , Poland

Exelixis Clinical #268

Lodz, , Poland

Exelixis Clinical Site #89

Poznan, , Poland

Exelixis Clinical Site #110

Braga, , Portugal

Exelixis Clinical Site #188

Guimarães, , Portugal

Exelixis Site #164

Lisbon, , Portugal

Exelixis Clinical Site #197

Lisbon, , Portugal

Exelixis Clinical Site #196

Loures, , Portugal

Exelixis Clinical Site #56

Porto, , Portugal

Exelixis Clinical Site #223

Porto, , Portugal

Exelixis Clinical Site #193

Vila Real, , Portugal

Exelixis Site #166

Moscow, , Russia

Exelixis Clinical Site #137

Saint Petersburg, , Russia

Exelixis Clinical Site #195

Saint Petersburg, , Russia

Exelixis Clinical Site #50

Singapore, , Singapore

Exelixis Clinical Site #87

Singapore, , Singapore

Exelixis Clinical Site #181

Singapore, , Singapore

Exelixis Clinical Site #20

Junggu, Daejeon, South Korea

Exelixis Clinical Site #49

Goyang-si, Gyeonggi-do, South Korea

Exelixis Clinical Site #60

Seongnam-si, Gyeonggi-do, South Korea

Exelixis Clinical Site #34

Hwasun, Jeollanam-do, South Korea

Exelixis Clinical Site #58

Busan, , South Korea

Exelixis Clinical Site #24

Busan, , South Korea

Exelixis Clinical Site #94

Daegu, , South Korea

Exelixis Clinical Site #21

Daegu, , South Korea

Exelixis Clinical Site #40

Gwangju, , South Korea

Exelixis Clinical Site #59

Seoul, , South Korea

Exelixis Clinical Site #46

Seoul, , South Korea

Exelixis Clinical Site #25

Seoul, , South Korea

Exelixis Clinical Site #48

Seoul, , South Korea

Exelixis Clinical Site #229

Elche, Alicante, Spain

Exelixis Clinical Site #220

Palma de Mallorca, Balearic Islands, Spain

Exelixis Clinical Site #12

Manresa, Barcelona, Spain

Exelixis Clinical Site #233

Santiago de Compostela, La Coruna, Spain

Exelixis Clinical Site #17

Alcorcón, Madrid, Spain

Exelixis Clinical Site #225

Oviedo, Principality of Asturias, Spain

Exelixis Clinical Site #274

Badalona, , Spain

Exelixis Clinical Site #228

Barcelona, , Spain

Exelixis Clinical Site #23

Barcelona, , Spain

Exelixis Clinical Site #255

Barcelona, , Spain

Exelixis Clinical Site #190

Barcelona, , Spain

Exelixis Clinical Site #226

Cadiz, , Spain

Exelixis Clinical Site #33

Córdoba, , Spain

Exelixis Clinical Site #28

Lugo, , Spain

Exelixis Clinical Site #131

Madrid, , Spain

Exelixis Clinical Site #248

Madrid, , Spain

Exelixis Clinical Site #236

Madrid, , Spain

Exelixis Clinical Site #251

Madrid, , Spain

Exelixis Clinical Site #13

Madrid, , Spain

Exelixis Clinical #270

Málaga, , Spain

Exelixis Clinical Site #29

Seville, , Spain

Exelixis Clinical #266

Kaohsiung City, , Taiwan

Exelixis Clinical Site #138

Kaohsiung City, , Taiwan

Exelixis Clinical Site #86

Taichung, , Taiwan

Exelixis Clinical Site #133

Taichung, , Taiwan

Exelixis Clinical Site #111

Tainan, , Taiwan

Exelixis Clinical Site #271

Tainan, , Taiwan

Exelixis Clinical #264

Taipei, , Taiwan

Exelixis Clinical #265

Taoyuan District, , Taiwan

Exelixis Clinical Site #102

Dnipro, , Ukraine

Exelixis Clinical Site #186

Dnipro, , Ukraine

Exelixis Clinical Site #76

Kyiv, , Ukraine

Exelixis Clinical Site #71

Lutsk, , Ukraine

Exelixis Clinical Site #205

London, England, United Kingdom

Exelixis Clinical Site #235

Surrey Quays, England, United Kingdom

Exelixis Clinical Site #241

Taunton, England, United Kingdom

Exelixis Clinical Site #249

Blackburn, Lancashire, United Kingdom

Exelixis Clinical Site #231

Northwood, Middlesex, United Kingdom

Exelixis Clinical Site #194

Swansea, Wales, United Kingdom

Countries

United States; Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; Czechia; France; Georgia; Germany; Greece; Hungary; Israel; Italy; Japan; Mexico; Poland; Portugal; Russia; Singapore; South Korea; Spain; Taiwan; Ukraine; United Kingdom

References

Agarwal N, Azad AA, Carles J, Matsubara N, Oudard S, Saad F, Merseburger AS, Soares A, McGregor BA, Zurawski B, Tsiatas M, North S, Bondarenko I, Alfie M, Bournakis E, Antonuzzo L, Evilevitch L, Simmons A, Wang F, Ferraldeschi R, Nandoskar P, Pal SK. Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial. Lancet Oncol. 2025 Jul;26(7):860-876. doi: 10.1016/S1470-2045(25)00209-8. Epub 2025 Jun 13.

Reference Type: DERIVED

PMID: 40523369 (View on PubMed)

Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghou F, Kerloeguen Y, Kimura A, Mohamed N, Panneerselvam A, Wang F, Pal S. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol. 2022 Mar;18(10):1185-1198. doi: 10.2217/fon-2021-1096. Epub 2022 Jan 17.

Reference Type: DERIVED

PMID: 35034502 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

XL184-315

Identifier Type: -

Identifier Source: org_study_id